Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
Vigil Neuroscience’s VG-3927: Promising Phase 1 Results and Strategic Positioning for Phase 2
Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated
Vigil Neuroscience shares rise on positive Alzheimer's trial data
Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 clinical trial for VG-3927, a potential treatment for Alzheimer's disease (AD).
Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update)
Vigil Neuroscience (VIGL) stock rises as the Sanofi (SNY)-backed biotech plans to advance its Alzheimer's candidate VG-3927 into a Phase 2 trial in Q3. Read more here.
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral
Analysts 'highly encouraged' by TREM2 reduction seen in Vigil's phase 1 Alzheimer's data
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival antibody.
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
Vigil Neuroscience's VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer's treatment; Phase 2 begins Q3 2025.
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial
WATERTOWN, Mass. - Vigil Neuroscience , Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company, has announced the progression of its Alzheimer’s disease (AD) candidate, VG-3927, into a Phase 2 ...
Nasdaq16d
Vigil Neuroscience Highlights 2024 Achievements and 2025 Milestones for Alzheimer’s and ALSP Treatments
Vigil Neuroscience, Inc. has announced its plans to report data from its Phase 1 clinical trial of VG-3927, a TREM2 agonist for Alzheimer’s disease, in the first quarter of 2025, and expects to ...
Yahoo Finance16d
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
“2024 was a year of strong operational execution, driven by the progress of our two TREM2 agonist programs, VG-3927 and iluzanebart, and a $40 million strategic investment from Sanofi,” said ...